SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-17-031600
Filing Date
2017-05-10
Accepted
2017-05-10 16:44:08
Documents
76
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q a17-11553_110q.htm 10-Q 1103934
2 EX-31.1 a17-11553_1ex31d1.htm EX-31.1 13082
3 EX-31.2 a17-11553_1ex31d2.htm EX-31.2 13066
4 EX-32.1 a17-11553_1ex32d1.htm EX-32.1 6526
5 EX-32.2 a17-11553_1ex32d2.htm EX-32.2 7037
  Complete submission text file 0001104659-17-031600.txt   5118009

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT nbrv-20170331.xml EX-101.INS 1007372
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nbrv-20170331.xsd EX-101.SCH 51995
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nbrv-20170331_cal.xml EX-101.CAL 56349
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nbrv-20170331_def.xml EX-101.DEF 157580
10 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT nbrv-20170331_lab.xml EX-101.LAB 415773
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nbrv-20170331_pre.xml EX-101.PRE 323022
Mailing Address LEBERSTRASSE 20 VIENNA C4 1110
Business Address LEBERSTRASSE 20 VIENNA C4 1110 43 (0)1 740 93-0
Nabriva Therapeutics AG (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: C4 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37558 | Film No.: 17831100
SIC: 2834 Pharmaceutical Preparations